Literature DB >> 26201618

Are we ready to use the hepatitis B surface antigen level to guide peginterferon treatment in HBeAg-negative chronic hepatitis B?

Henry Lik Yuen Chan1.   

Abstract

Entities:  

Year:  2012        PMID： 26201618     DOI： 10.1007/s12072-012-9385-0

Source DB:  PubMed          Journal:  Hepatol Int        ISSN： 1936-0533            Impact factor:   6.047


× No keyword cloud information.
  16 in total

1.  Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers.

Authors:  Maurizia Rossana Brunetto; Filippo Oliveri; Piero Colombatto; Francesco Moriconi; Pietro Ciccorossi; Barbara Coco; Veronica Romagnoli; Beatrice Cherubini; Giovanna Moscato; Anna Maria Maina; Daniela Cavallone; Ferruccio Bonino
Journal:  Gastroenterology       Date:  2010-05-05       Impact factor: 22.682

2.  Relationship between serum hepatitis B virus DNA and surface antigen with covalently closed circular DNA in HBeAg-negative patients.

Authors:  L Y Lin; V W S Wong; H J Zhou; H Y Chan; H L Gui; S M Guo; H Wang; L Huang; S S Bao; Q Xie; H L Y Chan
Journal:  J Med Virol       Date:  2010-09       Impact factor: 2.327

3.  Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B.

Authors:  I Tatulli; R Francavilla; G L Rizzo; V Vinciguerra; E Ierardi; A Amoruso; C Panella; A Francavilla
Journal:  J Hepatol       Date:  2001-12       Impact factor: 25.083

Review 4.  Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report.

Authors:  Henry Lik-Yuen Chan; Alex Thompson; Michelle Martinot-Peignoux; Teerha Piratvisuth; Markus Cornberg; Maurizia Rossana Brunetto; Hans L Tillmann; Jia-Horng Kao; Ji-Dong Jia; Heiner Wedemeyer; Stephen Locarnini; Harry L A Janssen; Patrick Marcellin
Journal:  J Hepatol       Date:  2011-06-28       Impact factor: 25.083

5.  Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study.

Authors:  Teresa Santantonio; Grazia Anna Niro; Emanuele Sinisi; Gioacchino Leandro; Maria Insalata; Angela Guastadisegni; Domenico Facciorusso; Eleonora Gravinese; Angelo Andriulli; Giuseppe Pastore
Journal:  J Hepatol       Date:  2002-06       Impact factor: 25.083

6.  Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers.

Authors:  Alexander J V Thompson; Tin Nguyen; David Iser; Anna Ayres; Kathy Jackson; Margaret Littlejohn; John Slavin; Scott Bowden; Edward J Gane; William Abbott; George K K Lau; Sharon R Lewin; Kumar Visvanathan; Paul V Desmond; Stephen A Locarnini
Journal:  Hepatology       Date:  2010-06       Impact factor: 17.425

7.  Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B.

Authors:  F Bonino; P Marcellin; G K K Lau; S Hadziyannis; R Jin; T Piratvisuth; G Germanidis; C Yurdaydin; M Diago; S Gurel; M-Y Lai; M R Brunetto; P Farci; M Popescu; P McCloud
Journal:  Gut       Date:  2006-11-24       Impact factor: 23.059

8.  Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients.

Authors:  Rami Moucari; Vincent Mackiewicz; Olivier Lada; Marie-Pierre Ripault; Corinne Castelnau; Michelle Martinot-Peignoux; Agnes Dauvergne; Tarik Asselah; Nathalie Boyer; Pierre Bedossa; Dominique Valla; Michel Vidaud; Marie-Hélène Nicolas-Chanoine; Patrick Marcellin
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

9.  Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a.

Authors:  Patrick Marcellin; Ferruccio Bonino; George K K Lau; Patrizia Farci; Cihan Yurdaydin; Teerha Piratvisuth; Rui Jin; Selim Gurel; Zhi-Meng Lu; Jian Wu; Matei Popescu; Stephanos Hadziyannis
Journal:  Gastroenterology       Date:  2009-03-19       Impact factor: 22.682

10.  Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients.

Authors:  Patrick Marcellin; Ferruccio Bonino; Cihan Yurdaydin; Stephanos Hadziyannis; Rami Moucari; Hans-Peter Kapprell; Vivien Rothe; Matei Popescu; Maurizia R Brunetto
Journal:  Hepatol Int       Date:  2012-03-23       Impact factor: 6.047
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.